Drugs / MT-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05138458 | Dec 2021 → Nov 2024 | mycosis fungoides, peripheral T-cell lymphoma, not otherwise specified | Myeloid Therapeutics | Suspended | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05138458 ↗ |
| Action | Deplete | “The modified myeloid cells recognize the tumor cells and are designed to target and kill them.” NCT05138458 ↗ |
| Modality | Cell therapy | “The myeloid cells are modified and later infused back into their veins.” NCT05138458 ↗ |
| Route | Intravenous | “infused back into their veins” NCT05138458 ↗ |